Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.
暂无分享,去创建一个
R. Rizzoli | J. M. Meyer | P. Vassalli | J. Bonjour | S. Bourrin | P. Ammann | I. Garcia | R. Rizzoli | Jean-Marc Meyer | J. Meyer
[1] S. Palle,et al. Effects of physical training on bone adaptation in three zones of the rat tibia , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] T. Martin,et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors , 1995, The Journal of experimental medicine.
[3] Y. Belkaid,et al. Transgenic mice expressing high levels of soluble TNF‐R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections , 1995, European journal of immunology.
[4] R. Kimble,et al. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. , 1995, Endocrinology.
[5] R. Jilka,et al. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.
[6] R. Kitazawa,et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. , 1994, The Journal of clinical investigation.
[7] A. Parfitt. Osteonal and hemi‐osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone , 1994, Journal of cellular biochemistry.
[8] R. Thompson,et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. , 1994, The Journal of clinical investigation.
[9] G. Ciliberto,et al. Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.
[10] R. Kimble,et al. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. , 1993, The Journal of clinical endocrinology and metabolism.
[11] T. Wronski,et al. Long‐term osteopenic changes in cancellous bone structure in ovariectomized rats , 1993, The Anatomical record.
[12] Harry K. Genant,et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.
[13] M. Horowitz. Cytokines and estrogen in bone: anti-osteoporotic effects. , 1993, Science.
[14] B. Riggs,et al. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor-alpha: lack of regulation by 17 beta-estradiol. , 1992, Endocrinology.
[15] R. Rizzoli,et al. Sequential and precise in vivo measurement of bone mineral density in rats using dual‐energy x‐ray absorptiometry , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] G. Passeri,et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.
[17] D. Kalu. The ovariectomized rat model of postmenopausal bone loss. , 1991, Bone and mineral.
[18] E. Puscheck,et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[19] G. Mundy,et al. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. , 1991, Endocrinology.
[20] M. Cecchini,et al. Production of granulocyte-macrophage (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) by rat clonal osteoblastic cell population CRP 10/30 and the immortalized cell line IRC10/30-myc1 stimulated by tumor necrosis factor alpha. , 1991, Endocrinology.
[21] M. Cecchini,et al. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. , 1990, Endocrinology.
[22] L. Avioli,et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Roodman,et al. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. , 1989, Endocrinology.
[24] T. Bringman,et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors , 1986, Nature.
[25] V. Nuti. [Microdetermination of phosphorus in organic compounds]. , 1972, Il Farmaco; edizione scientifica.
[26] H. Broxmeyer,et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.
[27] P. Vassalli,et al. The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.
[28] A. M. Parfitt,et al. Bone Histomorphometry: System for Standardization of Nomenclature, Symbols, and Units , 1988 .
[29] L. Melton,et al. Involutional osteoporosis. , 1986, The New England journal of medicine.